Honeywell Takes Flight In Autonomous Future With Civitanavi Acquisition

Honeywell to acquire Civitanavi Systems for €6.30 per share. Deal expected to close in Q3 2024, not subject to financing. Honeywell will gain new navigation solutions and strengthen their position in autonomous operations.

Honeywell International Inc (NASDAQ:HON) disclosed the intention to acquire all outstanding shares of Civitanavi Systems S.p.A.

Civitanavi provides position navigation and timing technology for the aerospace, defense, and industrial markets. 

The company will initiate a voluntary tender offer of €6.30 per share in cash (an equity value of approximately €200 million at closing).

The purchase price represents a premium of about 27.1% to the 30-day volume-weighted average trading price of Civitanavi’s stock, which ended on March 26, 2024, the last day of trading before the transaction’s announcement. 

The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions, and is not subject to any financing condition.

Honeywell has already secured the commitment of Civitanavi’s controlling shareholder, who owns approximately 66% of the outstanding shares.

The acquisition will further boost Honeywell’s capabilities to help its customers create autonomous operations in aircraft and other vehicles. 

The deal also supports Honeywell’s alignment of its portfolio, including the future of aviation and automation. 

Jim Currier, Honeywell Aerospace Technologies President & CEO, said, “With this acquisition, we will be able to immediately expand our offerings to customers in the European Union through Civitanavi’s navigation solutions, a capability we intend to further build out in the near-term.”

Honeywell held cash and equivalents of ~$8 billion as of December 31, 2023.

Investors can gain exposure to the stock via Gabelli Commercial Aerospace And Defense ETF (NYSE:GCAD) and Invesco Aerospace & Defense ETF (NYSE:PPA).

Price Action: HON shares closed higher by 1.27% at $201.00 on Tuesday.

Photo via Wikimedia Commons

Total
0
Shares
Related Posts
Read More

Oncolytics Biotech’s Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating The Anti-Cancer Activity Of Pelareorep-Paclitaxel Combination Therapy In HR+/HER2- Metastatic Breast Cancer At SABCS

Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /CNW/ -- Oncolytics

ONCY